Myeloid-derived suppressor cells (MDSCs) form a heterogeneous population of cells composed of early myeloid progenitor cells and immature myeloid cells, which strongly suppress pro-inflammatory immune cells in inflammatory diseases. Currently, it is unknown whether MDSCs contribute to atherosclerosis, a chronic inflammatory disease in which accumulation of lipoproteins in the arterial wall activates the immune system causing abnormal vascular remodelling and vessel occlusion. Here, we investigated whether and how MDSCs contribute to the development of atherosclerosis.
Introduction
Cardiovascular diseases such as stroke and myocardial infarction are the leading cause of death worldwide and are mainly caused by the development of atherosclerosis. Atherosclerosis is characterized by the progressive narrowing of medium and large arteries by formation of plaques, caused by lipid accumulation and excessive inflammatory immune processes in the arterial wall. Current treatment options reduce patients' relative risk by 30% but are inadequate to halt progression of cardiovascular disease with respect to plaque size or to reverse existing plaques, emphasizing an urgent need for new therapeutic strategies to inhibit atherosclerosis.
Inflammation is considered a key process in atherosclerotic plaque development and plaque rupture. 1, 2 The contribution of macrophages and T cells to the pathogenesis of atherosclerosis is well established, and the majority of T cells involved in plaque development are IFNgsecreting Th1 cells, which are activated by macrophages and dendritic cells loaded with atherosclerosis-specific antigens, such as oxidized LDL (oxLDL). Immune suppressor cells such as regulatory T cells (Tregs) can suppress these pro-atherogenic T cells and are now recognized as crucial modulators of inflammation in atherosclerosis, 3 suggesting that immune suppression may hold therapeutic promise.
Another suppressor cell type that may significantly impact the development of atherosclerosis is the myeloid-derived suppressor cell (MDSC). MDSCs comprise a heterogeneous population of CD11b
+-

Gr-1
+ cells that primarily consist of myeloid cell progenitors and precursors of granulocytes, macrophages, and dendritic cells. 4 In healthy individuals, immature myeloid cells (IMCs) differentiate into neutrophils, monocytes/macrophages, or dendritic cells. However, under pathological conditions, the microenvironment in the bone marrow promotes expansion of IMCs and prevents their regular differentiation, resulting in the development of MDSCs. Subsequently, these MDSCs migrate towards various tissues where they effectively suppress effector cells. 4 MDSCs have been extensively investigated in tumour immunology, but in the past few years, there has been accumulating evidence identifying MDSCs as potent suppressors of several autoimmune diseases including experimental autoimmune encephalomyelitis (EAE), 5, 6 graft vs. host disease, 7 rheumatoid arthritis, 8, 9 and type 1 diabetes. 10 A profound accumulation of MDSCs has been observed in the spleen, liver, and epididymal fat of high-fat diet fed obese ob/ob mice, and adoptive transfer of MDSCs improved the insulin response of these mice. 11 Moreover, levels of CD14 + HLA-DR 2/low MDSCs are elevated in acute coronary syndrome (ACS) patients. 12 Given their immunosuppressive capacity, MDSCs may represent a novel immunotherapeutical target to treat atherosclerosis, but up to date, the role of MDSCs in atherosclerosis has not been described.
To investigate whether and how MDSCs contribute to the development of atherosclerosis, we isolated bone marrow-derived CD11b
+-
Gr-1
+ cells from atherosclerotic LDL receptor deficient (LDLr 2/2 ) mice and analysed their phenotype and function. We performed an adoptive transfer experiment to explore their therapeutic potential and with that yielded important information and mechanistic insights into the role of MDSCs in atherosclerosis.
Methods
Animals
Female and male LDLr-deficient (LDLr 2/2 ) mice, 10 -12 weeks old, were obtained from Jackson Laboratories. The animals were kept under standard laboratory conditions and were fed a regular chow diet or Western-type diet (WTD) containing 0.25% cholesterol and 15% cocoa butter (Special Diet Services, Witham, Essex, UK). Diet and water were provided ad libitum. All animal work was approved by the regulatory authority of Leiden University and carried out in compliance with the Dutch government guidelines. Moreover, the animal experiments were performed conform the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. At sacrifice, mice were anaesthetized by a subcutaneous injection (120 mL) of a cocktail containing ketamine (40 mg/mL), atropine (50 mg/mL), and sedazine (6.25 mg/mL). After euthanization by cervical dislocation, the mice were exsanguinated by femoral artery transection followed by perfusion with PBS through the left cardiac ventricle. were isolated by a negative enrichment using an antibody cocktail containing biotin-labelled antibodies against CD5, CD45R, CD49b, CD117, F4/80, and TER119, which were added to the cells for 10 min at 48C. After centrifugation, the cells were resuspended in MACS buffer, and anti-Biotin-Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were added. Cells were incubated for 15 min at 48C. Subsequently, the cells were washed with MACS buffer, and CD11b + Gr-1 + cells were collected using an LS MACS Column (Miltenyi Biotec). Purity of the isolated CD11b + Gr-1 + cells was determined with flow cytometry and was seen to be routinely .95%. Phenotypic characterization of the MDSCs was performed using freshly isolated MDSCs from LDLr 2/2 mice, which were fed a WTD for 2 weeks. Expression of the following markers was determined with flow cytometry: CD14, CD115, CD49d, CD11c, CD62L, MHC I, MHC II, CD80, CD86, and CD40. All antibodies were purchased from eBioscience (Vienna) or Becton Dickinson (Mountain View, CA). FACS analysis was performed on a FACSCantoII (Becton Dickinson), and the acquired data were analysed using FlowJo software. Culture supernatants were analysed for cytokine concentrations using a Luminex bead-based multiplex assay (ProcartaPlex, eBioscience) specific for IL-10 and IFN-g on a Luminex Instrument (MAGPIX). Recombinant cytokine standards (eBioscience) were used to calculate cytokine concentrations, and data were analysed using Bio-Rad software.
Isolation of CD11b
Suppressive capacity of MDSCs
The suppressive capacity of MDSCs was determined by co-culture with splenocytes or CFSE-labelled CD4 + T cells. Splenocytes or T cells (2 × H-thymidine incorporation was measured using a liquid scintillation analyser (Tri-Carb 2900R). Responses are expressed as the mean counts per minute (cpm). To determine which suppressive factors are responsible for the MDSC-mediated T cell suppression, we cocultured CD11b
+ Gr-1 + cells from LDLr 2/ 2 mice in a 1:1 ratio with anti-CD3 (1 mg/mL) and anti-CD28 (0.5 mg/mL) activated splenocytes. Cells were cultured in the presence or absence of L-NMMA (0.5 mM, Cayman Chemicals), superoxide dismutase (SOD) (200 U/mL, Sigma-Aldrich), COX-2 inhibitor II (100 nM, Calbiochem), Nor-NOHA (0.5 mM, Calbiochem), or anti-IFN-g (20 mg/mL, provided by Louis Boon). Proliferation was measured as described above. 
In vivo tracking of CFSE-labelled MDSCs
Initiation of atherosclerosis
Atherosclerosis was induced in female LDLr 2/2 mice by feeding a WTD for 6 weeks. During these 6 weeks, mice received an i.v. injection of 6 × 10 6 MDSCs (n ¼ 12) or PBS (n ¼ 12) every 10 days. After 6 weeks, mice were sacrificed, and tissues were harvested after in situ perfusion using PBS. Tissues were stored in Zinc Formal-Fixx (Shandon, Inc., Pittsburgh, USA) or snap frozen in nitrogen and stored at 2808C until further use. In a separate experiment using a similar set-up as described above, we studied the role of MDSCs in male LDLr 2/2 mice (MDSCs group n ¼ 12 vs.
PBS group n ¼ 9).
Serum cholesterol levels
During the experiments, mice were weighed, and blood samples were obtained by tail vein bleeding. The total cholesterol levels in serum were determined using enzymatic colorimetric procedures (Roche/Hitachi, Mannheim, Germany). Precipath (Roche/Hitachi) was used as an internal standard.
Histological analysis and morphometry
Cryosections of the aortic root (10 mm) were made and stained with Oil-red-O. Lesion collagen content was determined with a Masson's trichrome staining. Furthermore, corresponding sections on separate slides were stained immunohistochemically with an antibody directed against a macrophage-specific antigen (Moma-2, monoclonal rat IgG2b, diluted 1:1000). Goat anti-rat IgG alkaline phosphatase conjugate (dilution 1:100) was used as a secondary antibody and nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as enzyme substrates. To determine the number of CD3 + T cells in the intima and in adventitia, a CD3
staining was performed using anti-mouse CD3 (1:100, SP7, Immunologic, The Netherlands). Morphology was studied using a Leica DM-RE microscope and LeicaQwin software (Leica Imaging Systems, Cambridge, UK).
Flow cytometry
At sacrifice of the atherosclerosis experiment, blood and spleen cells were isolated (n ¼ 5 per group). Single-cell suspensions were obtained by mashing the organs through a 70 mm cell strainer. Red blood cells were removed from blood and splenocyte suspensions using erythrocyte lysis buffer (0. To detect Th1/Th2/Th17/Treg cells, cells were fixed and permeabilized according to the manufacturer's protocol (eBioscience). Subsequently, the cells were stained for T-bet, GATA-3, RORgt, or Foxp3. To detect apoptotic splenocytes, an Annexin-V/PI staining was performed according to the manufacturer's protocol (eBioscience). All antibodies were purchased from eBioscience and Becton Dickinson. FACS analysis was performed as described above.
Serum antibody detection
IgM, IgG1, and IgG2c levels against oxLDL were detected in serum using Abs recognizing mouse IgM, IgG1, IgG2c, and HRP-labelled goat anti-rat Ig (BD Pharmingen). oxLDL (5 mg/mL) was dissolved in NaHCO 3 / Na 2 CO 3 buffer (pH 9.6) and was coated overnight onto a flat-bottom 96-well high binding plate (Corning, NY). Serum samples were diluted 1:1 in PBS, and the absorbance was detected at 450 nm.
MDSC subsets
To detect two different subsets of MDSCs [i.e. Ly6G + Ly6C low granulocytic
MDSCs (gr-MDSCs) vs. Ly6G 2 Ly6C hi monocytic MDSCs (mo-MDSCs)], the isolated cells were stained with anti-Ly6G and anti-Ly6C and analysed by flow cytometry. To evaluate the effect of atherosclerosis on both subsets, the percentages of both subsets in the bone marrow of LDLr 2/2 mice after WTD feeding for 0, 4, or 8 weeks were determined again by flow cytometry. In addition, we isolated both mo-and gr-MDSCs by adding biotinylated anti-Ly6G or anti-Ly6C, respectively, to the antibody cocktail explained above. Purity of both subsets upon isolation was determined by flow cytometry and by a May-Grünwald-Giemsa staining (Sigma-Aldrich).
To perform the Giemsa staining, MDSCs were centrifuged on a microscope slide using a Cytospin centrifuge (Thermo Shandon, Pittsburgh, USA).
Subsequently, slides were fixed with Zinc Formal-Fixx (Thermo Shandon) and stained according to the manufacturer's protocol.
Detection of nitric oxide
The production of nitric oxide (NO) by MDSCs in co-culture with activated splenocytes, either in the presence or absence of L-NMMA or anti-IFN-g, was determined using the Griess method according to the manufacturer's protocol (Sigma-Aldrich). NaNO 2 was used as internal standard, and the absorbance was measured at 540 nm.
Quantitative polymerase chain reaction
To detect changes in the gene expression of different key markers of MDSCs due to a WTD feeding, mRNA was extracted from MDSCs from chow-and WTD-fed mice using the guanidium isothiocyanate (GTC) method and reverse transcribed (RevertAid M-MuLV reverse transcriptase). Quantitative gene expression analysis was performed on a 7500 Fast Real-Time PCR system (Applied Biosystems, CA) using SYBR green technology. The following primer pairs were used: 
Statistical analysis
All data are expressed as mean + SEM. Normality of data distribution was determined with a Shapiro -Wilk normality test. An unpaired two-tailed Student's t-test was used to compare normally distributed data between two groups of animals. To correct for multiple t-tests on the same sample, we used the Bonferroni method. A one-way ANOVA with Dunnett's multiple comparison post-test was performed for multiple comparisons on the same set of data. A two-way ANOVA with Dunnett's multiple comparison post-test was performed for multiple comparisons on the same set of data containing two variables. Probability values of P , 0.05 are considered significant. Data were analysed using GraphPad Prism version 5.0 software (GraphPad Software, La Jolla, CA, USA).
Results
MDSCs expand in LDLr
2/2 mice during atherosclerosis
MDSCs are described as CD11b
+ Gr-1 + cells that are formed in the bone marrow under pathological conditions. To determine whether MDSC expansion is promoted during atherosclerosis, we isolated CD11b + Gr-1 + cells from bone marrow of LDLr 2/ 2 mice fed a WTD for 2 weeks by immunomagnetic negative enrichment and determined their purity by flow cytometry (.95%, Figure 1A ). To assess whether these CD11b + Gr-1 + cells are indeed MDSCs, we characterized the surface marker profile. As shown in Figure 1B , our isolated CD11b + Gr-1 + cells express MDSC markers CD14, CD115, CD49d, CD62L, and MHCI and are negative for CD11c, CD80, CD86, CD40, and MHCII. To determine whether these cells exert a suppressive function, we performed a suppression assay using CD11b + Gr-1 + Figure 1 MDSCs expand in LDLr 2/2 mice during atherosclerosis. To determine whether MDSCs develop during atherosclerosis, CD11b + Gr-1 + cells were isolated from bone marrow of female LDLr 2/2 mice fed a WTD for 2 weeks via negative enrichment. First, the purity was determined with flow cytometry (A). Secondly, the cells (pooled from n ¼ 3) were phenotypically characterized as MDSCs by staining of the following cell markers known to be present on MDSCs: CD14, CD115, CD49d, CD62L, MHCI, or absent on MDSCs: CD11c, MHCII, CD80, CD86, and CD40, representative data of five independent experiments are shown (B). A suppression assay confirmed the suppressive capacity of these CD11b + Gr-1 + cells (MDSCs) as they potently suppressed anti-CD3/CD28-induced proliferation of splenocytes (C ). Data are shown as the mean cpm of three animals, and for each animal, the cpm was determined as a mean of a triplicate culture. Representative data of five independent experiments are shown. CFSE-labelled T cells were also co-cultured with MDSCs (n ¼ Figure 1E) . Moreover, increasing numbers of MDSCs in co-cultures decreased IFN-g levels in the supernatant ( Figure 1F) , whereas IL-10 levels were increased ( Figure 1G) , indicative of an anti-inflammatory response. To investigate whether MDSCs expand during atherosclerosis, we fed LDLr 2/ 2 mice a WTD for 0, 2, 4, 6, and 8 weeks and isolated CD11b + Gr-1 + cells from the bone marrow. We observed a significant two-fold increase in MDSCs during atherosclerosis development ( Figure 1H ). Absolute numbers of CD11b + Gr-1 + MDSCs show a similar trend ( Figure 1I ).
Adoptive transfer of MDSCs reduces the development of atherosclerosis
To assess the role of MDSCs in atherosclerosis, we first designed a schedule for adoptive transfer of MDSCs into LDLr 2/2 mice. To track
MDSCs after injection, we labelled MDSCs with CFSE and injected these cells i.v. into LDLr 2/ 2 mice. Two hours after injection, we detected most of the CFSE-positive cells in the spleen, lymph nodes, and white adipose tissue, indicating a migration to primary and secondary lymphoid organs and fat tissue (Figure 2A ). Three and nine days after adoptive transfer of MDSCs, we still detected increased CD11b + Gr-1 + cells in the blood and spleen, while no CD11b
were found in the lymph nodes ( Figure 2B ). Based upon these findings, female LDLr 2/2 mice were fed a WTD for 6 weeks and every 10 days received 6 × 10 6 MDSCs isolated from bone marrow of LDLr 2/2 mice that had been fed a WTD for 2 weeks ( Figure 3A) . During the experiment, no difference in body weight was observed ( Figure 3B) , and total plasma cholesterol levels were unaffected by adoptive transfer of MDSCs ( Figure 3C ). Figure 3D ). No significant difference in lesion collagen content as determined by Masson's trichrome staining was detected between MDSC-treated mice (10.4 + 0.8%) and control mice (12.8 + 1.6%, Figure 3E ). Furthermore, no difference in macrophage content was observed (control: 73.0 + 2.2% and MDSC: 75.4 + 1.6%, Figure 3F ). In a separate experiment, we confirmed the atheroprotective effect of MDSCs in male LDLr 2/2 mice. As shown in
Supplementary material online, Figure S1 , 
MDSCs reduce adventitial T cells and affect T cell subsets
Since MDSCs from atherosclerotic mice are potent suppressors of T cells in vitro (Figure 1) , we checked whether our MDSC treatment also affected T cell numbers in atherosclerotic lesions of LDLr 2/2 mice. Representative cross sections of the aortic root were stained for CD3 + T cells ( Figure 4A ). Although we found no difference in the number of T cells within the atherosclerotic lesions ( Figure 4B ), we observed a 54% reduction in the number of adventitial T cells in MDSC-treated mice compared with control mice ( Figure 4C ). At sacrifice, there were no differences in the percentages of total CD4 + and CD8 + T cells in the blood and spleen of MDSC-treated and control mice (see Supplementary material online, Figure S2A and B). However, we did observe an effect on the activation status of the T cells as shown draining lymph nodes 3 and 9 days after injection was determined with flow cytometry (B). Statistical analysis of B was performed using unpaired twotailed Student's t-test. *P , 0.05, ***P , 0.001.
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by increased percentages of naïve CD4 + CD44 low CD62L high and CD8 + CD44 low CD62L high T cells ( Figure 4D ) and decreased percentages of effector CD4 + CD62L low and CD8 + CD62L low T cells ( Figure 4E ) in the spleen of MDSC-treated LDLr 2/2 mice. To evaluate whether adoptive transfer of MDSCs affected specific effector T cell subsets, splenocytes were stained for the transcription factors T-bet, GATA-3, RORgt, and Foxp3, which control the differentiation of Th0 cells into Th1, Th2, Th17 cells, and Tregs, respectively. While the number of splenic Th2 or Treg cells (see Supplementary material online, Figure S2C and D, respectively) was not affected by MDSC treatment, we did detect significantly reduced levels of Th1 cells in MDSC-treated mice (6.4 + 0.4%) compared with control mice (12.9 + 0.3%, P , 0.001, Figure 4F ). Moreover, we found reduced percentages of RORgt expressing CD4 + T cells (2.5 + 0.1 vs. 5.1 + 0.2% in control mice, P , 0.001) in MDSC-treated mice ( Figure 4F ). In line with these findings, male MDSC-treated mice also show reduced effector T cells and reduced Th1 and Th17 cells (see Supplementary material online, Figure S1E and F).
Reduced percentages of B2 cells in MDSC-treated mice
In atherosclerosis, the role of several subsets of B cells has been described, including pro-atherogenic B2 cells. We observed a 30% decrease in circulating B2 cells in MDSC-treated mice (15.2 + 1.0%) in comparison with control mice (21.6 + 2.1%, P , 0.05, Figure 4H ).
This reduction in B2 cells was also observed in male LDLr 2/2 mice treated with MDSCs (see Supplementary material online, Figure S1G ). Figure 4I ).
To see whether this change in B cell numbers and proliferation influenced antibody production, we measured oxLDL-specific antibodies in serum. No differences were detected in oxLDL-specific IgM, IgG1, or IgG2c in serum of MDSC-treated mice in comparison with control mice (see Supplementary material online, Figure S3 ). Th2 cytokines, such as IL-4, IL-10, and IL-13. 15 Therefore, both subsets might be regulated differently during atherosclerosis development. To assess how these subsets are affected during atherosclerosis, we fed LDLr 2/2 mice a WTD for 0, 4, or 8 weeks. As shown in Figure 5A , CD11b + Gr-1 + cells isolated from bone marrow of WTD-fed mice contain both a monocytic and granulocytic subsets. Flow cytometric analysis showed that despite the greater numbers of gr-MDSCs within the total MDSC population ( Figure 5B) , the percentage of mo-MDSCs Figure 3 Adoptive transfer of MDSCs reduces atherosclerotic lesion development, independent of cholesterol levels. Female LDLr 2/2 mice (n ¼ 12 per group) were fed a WTD for 6 weeks while receiving 4 injections of MDSCs (A). During the experiment, mice were weighed (B), and at sacrifice, total serum cholesterol was determined (C). Representative cross sections of lesion formation in the aortic valve area stained with Oil-Red-O and haematoxylin are shown, and lesion size was determined (D). Sections of the aortic root were stained for collagen using Masson's trichrome staining. The percentage of collagen relative to the lesion size was determined (E). Relative macrophage content was determined with a MOMA-2 staining and quantified (F). Bars ¼ 100 mm. Statistical analysis of B was performed using one-way ANOVA. Statistical analysis of C-F was performed using unpaired two-tailed Student's t-test. **P , 0.01.
Increased percentage of mo-MDSCs during atherosclerosis
increases upon WTD feeding, whereas the percentage of gr-MDSCs is significantly lower after WTD feeding ( Figure 5C ).
MDSCs suppress in an NO-and IFN-g-dependent manner
Mo-MDSCs suppress T cells especially by inducible nitric oxide synthase (iNOS), whereas gr-MDSCs suppress mainly by arginase 1 (arg-1). 16 Both iNOS and arg-1 compete for their common substrate L-arginine. iNOS consumes L-arginine to NO, which renders T cells non-responsive to IL-2. 17 In contrast, arg-1 converts L-arginine to urea and polyamines, which reduces the availability of L-arginine and subsequently impairs T cell function by loss of CD3z expression.
18
Both arg-1 and iNOS can generate reactive oxygen species (ROS), which inhibit T cell function via nitration of the T cell receptor, thereby impairing the T cell -antigen -MHC interaction. 19 In addition, MDSCs produce prostaglandins, which contribute to the immunosuppressive function by up-regulating the arg-1 expression on MDSCs. 20 To determine the mechanism through which MDSCs suppress immune cell responses in atherosclerosis, we added Nor-NOHA, SOD, a COX-2 inhibitor, and L-NMMA to co-cultures of MDSCs and splenocytes isolated from WTD-fed mice, to suppress the action of arg-1, ROS, Statistical analysis was performed using unpaired two-tailed Student's t-test, and we corrected for multiple t-tests on the same sample using the Bonferroni method. *P , 0.05, **P , 0.01, ***P , 0.001.
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prostaglandins, and NO synthase, respectively ( Figure 5D and see Supplementary material online, Figure S4 ). Whereas addition of Nor-NOHA, SOD, and a COX-2 inhibitor did not affect the suppressive function of MDSCs (97, 99, and 93% suppression, respectively), the common NO synthase inhibitor L-NMMA completely abrogated the suppressive capacity of the MDSCs from atherosclerotic mice. Since iNOS expression is promoted by IFN-g, we also added anti-IFN-g to the co-cultures. Similar to L-NMMA, anti-IFN-g inhibited MDSC-mediated suppression. This shows that the suppressive capacity of MDSCs from atherosclerotic mice is dependent on NO and IFN-g. In addition, we observed an increase in the production of NO in a co-culture of MDSCs with activated splenocytes, which could be blocked by the addition of L-NMMA or anti-IFN-g ( Figure 5E ). These findings suggest that the atheroprotective effect of adoptive transfer of MDSCs is driven by the mo-MDSCs. Moreover, we observed a differential expression of arg-1 and STAT-1 in MDSCs isolated from chow-fed mice in comparison with WTD-fed mice. Arg-1, associated with gr-MDSCs, was expressed lower in WTD MDSCs, whereas STAT-1, the main regulator activated by IFN-g signalling, the chemokine receptor CCR2, and CD49d, all associated with mo-MDSCs were expressed significantly higher (see Supplementary material online, Figure S5 ). 21, 22 In addition, upon WTD feeding, MDSCs increasingly expressed the anti-atherogenic and T cell suppressing cytokine TGF-b. To establish the exact contribution of mo-MDSCs and gr-MDSCs to the MDSC-mediated inhibition of T cell proliferation, we isolated CD11b + Ly6G 2 Ly6C high and CD11b + Ly6G + Ly6C low cells from the bone marrow of LDLr 2/2 mice fed a WTD for 2 weeks by an immunomagnetic negative enrichment. A Giemsa staining of these MDSCs showed morphometric differences between both the gr-MDSCs (ring-shaped multilobed nuclei) and mo-MDSCs (mononuclear cells), of which the purity (.95%) was checked by flow cytometry ( Figure 5F ). We performed a suppression assay with titrated numbers of mo-MDSCs or gr-MDSCs in co-culture with anti-CD3/ CD28-stimulated splenocytes isolated from WTD-fed LDLr 2/ 2 mice. As shown in Figure 5G , mo-MDSCs completely abolished splenocyte proliferation, even when present in low numbers (P , 0.001), whereas gr-MDSCs were not able to inhibit splenocyte proliferation at all ( Figure 5H ). To test the mechanism of MDSC-mediated inhibition of splenocyte proliferation, a suppression assay was performed in the presence of L-NMMA (0.5 mM, NO synthase inhibitor) and anti-IFN-g (20 mg/mL) (D). The suppression assay was performed with MDSCs and splenocytes isolated from 5 mice fed a WTD for 2 weeks. Data are shown as the mean cpm of 5 animals, and for each animal, the cpm was determined as a mean of a triplicate culture. NO production by MDSCs in these co-cultures with splenocytes with or without L-NMMA (0.5 mM) and anti-IFN-g (10 mg/mL) was determined using the Griess method (E). To investigate the contribution of mo-MDSCs and gr-MDSCs to MDSC-mediated inhibition of T cell proliferation, we isolated mo-and gr-MDSCs from 5 female mice fed a WTD for 2 weeks via immunomagnetic negative enrichment by adding biotinylated anti-Ly6G and anti-Ly6C, respectively (F) and a splenocyte suppression assay with mo-(G) and gr-MDSCs (H ) was performed. Statistical analysis of B -D, G, and H was performed using one-way ANOVA. E was analysed using twoway ANOVA. *P , 0.05, **P , 0.01, ***P , 0.001.
Discussion
In this study, we investigate the inhibitory potential of MDSCs in atherosclerosis. MDSCs develop in the bone marrow during inflammatory diseases as a protective negative feedback mechanism and migrate to inflamed tissue where they are powerful suppressors of immune responses. Although accumulating evidence implicates MDSCs as potent suppressors of several autoimmune diseases, 5, 7, 11, 23, 24 23, 30 Notably, we did not observe increased percentages of Tregs upon MDSC treatment, which is also described as one of the mechanisms through which MDSCs can suppress T cells. 10, 32 Besides suppressing T cell function, we showed that MDSC-treated mice also have reduced circulating B2 cells, possibly as a consequence of impaired proliferative capacity. B2 cells comprise the majority of circulating B cells and reside in lymphoid tissues. In atherosclerosis, B2 cells are considered pro-atherogenic since anti-CD20-mediated depletion of B2 cells ameliorates atherosclerosis and a B2 cell transfer into ApoE 2/2 mice aggravates atherosclerosis. 33, 34 Consistent with our findings, Green et al. showed that MDSCs, especially mo-MDSCs, can inhibit B cell proliferation. 24 MDSCs have been described as suppressors of T cell responses by several factors such as arg-1, iNOS, ROS, and NO. Our data show an important role of NO produced by iNOS and IFN-g in MDSC-mediated T cell suppression during atherosclerosis. Previously, it has been shown that iNOS-deficient MDSCs are insufficient to suppress the proliferation of T cells. 13, 30 In addition, and in line with our findings, IFN-g blockade abolishes MDSC-mediated T cell suppression. 13 IFN-g is the main activator of STAT1, and mo-MDSCs from Stat1 2/ 2 mice show significant reduced suppressive capacity compared with control MDSCs. 13 Therefore, IFN-g is likely the main inducer of mo-MDSCs and thus regulates iNOS expression and subsequent NO production. In atherosclerotic LDLr 2/2 mice, a Th1-biased environment may contribute to this IFN-g/iNOS-dependent mechanism of MDSC-mediated T cell suppression, although the suppressive capacity or the number of these MDSCs is not sufficient to completely dampen the immune response in atherosclerosis. Concomitantly, STAT-1 expression was significantly increased in MDSCs from atherosclerotic mice compared with non-atherosclerotic mice. Future research using STAT1-or iNOS-deficient MDSCs could provide additional mechanistic evidence on how MDSCs inhibit atherosclerosis. Notably, despite the importance of IFN-g for MDSC function, we show that in an in vitro suppression assay, IFN-g levels decrease upon increasing MDSC:T cell ratios. We believe MDSCs are immediately activated after co-culture with T cells and react to IFN-g produced by the T cells. At a 1:1 MDSC:T cell ratio where MDSCs exert optimal suppression, there is still 12 ng/mL IFN-g present in the supernatant. This concentration is sufficient for MDSC function and the reduced IFN-g levels observed in these co-cultures are a consequence of reduced IFN-g production by T cells.
Although we isolated CD11b + Gr-1 + MDSCs from atherosclerotic LDLr 2/2 mice and adoptively transferred both mo-and gr-MDSC subsets, it seems that mo-MDSCs are most likely responsible for the observed inhibition of atherosclerosis. Previous studies have shown that mo-MDSCs often exhibit more potent suppressive activity than gr-MDSCs. 13, 35, 36 However, although arg-1 blockade with Nor-NOHA did not interfere with the inhibitory capacity of MDSCs from atherosclerotic mice, it remains possible that our MDSCs also partially act via arg-1 since the in vitro microenvironment of splenocytes isolated from atherosclerotic LDLr 2/2 mice differs from the in vivo microenvironment in the atherosclerotic lesion. Arg-1 can be induced by IL-4, IL-10, and IL-13, cytokines that are differentially regulated during atherosclerosis development. Therefore, it is possible that MDSCs exhibit distinct biological activities depending on the microenvironment in the different pathological stages of atherosclerosis. A recent study shows that patients suffering from ACS have an increased frequency of circulating CD14
+-
HLA-DR
2/low MDSCs in comparison with stable angina (SA) or control patients. 12 Interestingly, MDSCs from ACS patients were more potent suppressors of T cell proliferation than those from SA or control patients and acted partially via arg-1, associated with gr-MDSCs. The relative potency of mo-and gr-MDSCs to provoke immune suppression in atherosclerosis will be an area of future investigation. Nowadays, a lot of research is exploring the use of Tregs to regulate pathogenic immune responses in atherosclerosis. MDSCs could provide a more beneficial approach to inhibit atherosclerosis than an adoptive transfer of Tregs because besides inducing Tregs themselves MDSCs suppress numerous immune cells through mechanisms that differ from those used by Tregs, thereby eliciting a stronger antiinflammatory response. 32, 37 However, in this study, we do not observe different Treg numbers in MDSC-treated mice despite increased IL-10 in MDSC:T cell co-cultures.
To test the feasibility of MDSCs as a potential clinical immunotherapy, more research must be performed to identify whether and where MDSCs expand in cardiovascular patients and whether MDSC levels and function correlate to plasma cholesterol levels, occurrence of cardiovascular events, and other parameters contributing to atherosclerosis. Ultimately, it would be ideal to translate these findings in a treatment plan using cellular therapy or targeting molecules important for the function of MDSCs. Recent studies have shown that expression of costimulatory and co-inhibitory molecules such as CD40 38 
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